PKCθ/PRKCQ Antibody [L3H13] Datasheet

Biological Description

Specificity	PKCθ/PRKCQ Antibody [L3H13] detects endogenous levels of total PKCθ/PRKCQ protein.
Background	PKCθ (PRKCQ), a novel serine/threonine kinase of the protein kinase C family, predominantly localizes to the immune synapse of T lymphocytes, where it orchestrates signal transduction from T cell receptor (TCR) and CD28 engagement to drive activation, differentiation, and effector functions. It features a C1 domain for diacylglycerol binding and a kinase domain that undergoes conformational activation upon TCR-induced translocation to the central supramolecular activation complex (cSMAC). Upon antigen stimulation, PKCθ complexes with CARMA1, BCL10, and MALT1 to activate the CBM signalosome, catalyzing IKKβ phosphorylation through oligomerization and K63-linked polyubiquitination of NEMO, which liberates NF-κB dimers (p65/p50) for nuclear translocation and transcription of IL-2, IFN-γ, and survival genes; concurrently, PKCθ phosphorylates CARD11 to amplify AP-1 (c-Jun/Fos) via JNK and ERK cascades while cooperating with calcineurin to dephosphorylate NFAT for optimal cytokine synergy. This positions PKCθ at the crux of the TCR-CD28-NF-κB/AP-1-NFAT axis, selectively required for Th1/Th2/Th17 differentiation and regulatory T cell suppressive function, while dispensable for thymocyte development. It governs immune homeostasis, allograft tolerance, and antiviral responses, making it a prime target for researchers dissecting T cell polarity in live-cell imaging or profiling pathway dominance via kinase-dead mutants in Jurkat models. Genetic ablation reveals profound defects in Th2-mediated immunity and experimental autoimmune encephalomyelitis.

Specificity

PKCθ/PRKCQ Antibody [L3H13] detects endogenous levels of total PKCθ/PRKCQ protein.

Background

PKCθ (PRKCQ), a novel serine/threonine kinase of the protein kinase C family, predominantly localizes to the immune synapse of T lymphocytes, where it orchestrates signal transduction from T cell receptor (TCR) and CD28 engagement to drive activation, differentiation, and effector functions. It features a C1 domain for diacylglycerol binding and a kinase domain that undergoes conformational activation upon TCR-induced translocation to the central supramolecular activation complex (cSMAC). Upon antigen stimulation, PKCθ complexes with CARMA1, BCL10, and MALT1 to activate the CBM signalosome, catalyzing IKKβ phosphorylation through oligomerization and K63-linked polyubiquitination of NEMO, which liberates NF-κB dimers (p65/p50) for nuclear translocation and transcription of IL-2, IFN-γ, and survival genes; concurrently, PKCθ phosphorylates CARD11 to amplify AP-1 (c-Jun/Fos) via JNK and ERK cascades while cooperating with calcineurin to dephosphorylate NFAT for optimal cytokine synergy. This positions PKCθ at the crux of the TCR-CD28-NF-κB/AP-1-NFAT axis, selectively required for Th1/Th2/Th17 differentiation and regulatory T cell suppressive function, while dispensable for thymocyte development. It governs immune homeostasis, allograft tolerance, and antiviral responses, making it a prime target for researchers dissecting T cell polarity in live-cell imaging or profiling pathway dominance via kinase-dead mutants in Jurkat models. Genetic ablation reveals profound defects in Th2-mediated immunity and experimental autoimmune encephalomyelitis.

Usage Information

Application

WB, IHC, FCM

Dilution

WB	IHC	FCM
1:1000	1:2000	1:50

Reactivity

Human

Source

Rabbit Monoclonal Antibody

MW

82 kDa

Storage Buffer

PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage
(from the date of receipt)

-20°C (avoid freeze-thaw cycles), 2 years

References

https://pubmed.ncbi.nlm.nih.gov/17544292/
https://pubmed.ncbi.nlm.nih.gov/20923402/

Application Data

WB

Validated by Selleck

Lane 1: Jurkat, Lane 2: MOLT4